| 1 | Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary. (Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA) Immunotherapy 2023 Aug;15(11):787-797 6 Citations |
| 1 | Prospects for targeting ACKR1 in cancer and other diseases. (Crawford KS, Volkman BF) Front Immunol 2023;14:1111960 32 Citations |
| 3 | Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. (Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, Nooka AK, Stadtmauer E, Micallef IN, McGuirk J, Costa L, Juckett MB, Shah N, Champlin RE, Usmani SZ, Farag SS, Nishihori T, Roy V, Bodiford A, Barnes YJ, Drea EJ, Hari P, Hamadani M) Haematologica 2023 Aug 01;108(8):2249-2254 5 Citations |
| 1 | Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. (Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD Jr, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PM) Transplant Cell Ther 2023 Mar;29(3):174.e1-174.e10 47 Citations |
| 1 | Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. (Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA) J Am Acad Dermatol 2023 Jan;88(1):40-51 237 Citations |
| 1 | Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. (Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG) J Allergy Clin Immunol 2022 Jun;149(6):2010-2020.e8 58 Citations |
| 4 | An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. (Badar T, Dhakal B, Szabo A, Padmanabhan A, Johnson BD, Heidtke S, Esselmann J, Chhabra S, Hamadani M, Hari P, D'Souza A) J Clin Apher 2019 Dec;34(6):686-691 3 Citations |
| 4 | Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. (Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM) Blood Adv 2019 Mar 26;3(6):875-883 32 Citations |
| 1 | Biased antagonism of CXCR4 avoids antagonist tolerance. (Hitchinson B, Eby JM, Gao X, Guite-Vinet F, Ziarek JJ, Abdelkarim H, Lee Y, Okamoto Y, Shikano S, Majetschak M, Heveker N, Volkman BF, Tarasova NI, Gaponenko V) Sci Signal 2018 Oct 16;11(552) 38 Citations |
| 1 | Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. (Papp K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, Girgis IG, Kundu S, Banerjee S) N Engl J Med 2018 Oct 04;379(14):1313-1321 347 Citations |
| 1 | Artemisinin Derivatives and Synthetic Trioxane Trigger Apoptotic Cell Death in Asexual Stages of Plasmodium. (Gunjan S, Sharma T, Yadav K, Chauhan BS, Singh SK, Siddiqi MI, Tripathi R) Front Cell Infect Microbiol 2018;8:256 41 Citations |
| 1 | A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation. (Haverkos BM, Huang Y, Elder P, O'Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, Andritsos LA, Devine SM, Jaglowski SM) Bone Marrow Transplant 2017 Apr;52(4):561-566 9 Citations |
| 1 | Collection of hematopoietic CD34 stem cells in rhesus macaques using Spectra Optia. (Haynes LD, Coonen J, Post J, Brunner K, Bloom D, Hematti P, Kaufman DB) J Clin Apher 2017 Oct;32(5):288-294 8 Citations |
| 4 | Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. (Dhakal B, Veltri LW, Fenske TS, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Esselman J, Watkins K, Pasquini MC, D'Souza A, Hari P, Kanate AS, Hamadani M) Biol Blood Marrow Transplant 2016 Oct;22(10):1773-1780 8 Citations |
| 1 | Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use. (Veltri L, Cumpston A, Shillingburg A, Wen S, Luo J, Leadmon S, Watkins K, Craig M, Hamadani M, Kanate AS) Cytotherapy 2015 Dec;17(12):1785-92 33 Citations |
| 1 | Discovery of bisamide-heterocycles as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake. (Dockendorff C, Faloon PW, Germain A, Yu M, Youngsaye W, Nag PP, Bennion M, Penman M, Nieland TJ, Dandapani S, Perez JR, Munoz B, Palmer MA, Schreiber SL, Krieger M) Bioorg Med Chem Lett 2015 Jun 15;25(12):2594-8 11 Citations |
| 1 | Heteromerization of chemokine (C-X-C motif) receptor 4 with α1A/B-adrenergic receptors controls α1-adrenergic receptor function. (Tripathi A, Vana PG, Chavan TS, Brueggemann LI, Byron KL, Tarasova NI, Volkman BF, Gaponenko V, Majetschak M) Proc Natl Acad Sci U S A 2015 Mar 31;112(13):E1659-68 63 Citations |
| 5 | Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. (Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, Hari PN, Hamadani M) Bone Marrow Transplant 2015 Apr;50(4):610-2 7 Citations |
| 7 | Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. (Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2014 Dec;20(12):1926-31 26 Citations |
| 1 | Influence of a dual-injection regimen, plerixafor and CXCR4 on in utero hematopoietic stem cell transplantation and engraftment with use of the sheep model. (Goodrich AD, Varain NM, Jeanblanc CM, Colon DM, Kim J, Zanjani ED, Hematti P) Cytotherapy 2014 Sep;16(9):1280-93 8 Citations |
| 1 | Chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3 regulate vascular α₁-adrenergic receptor function. (Bach HH 4th, Wong YM, Tripathi A, Nevins AM, Gamelli RL, Volkman BF, Byron KL, Majetschak M) Mol Med 2014 Oct 13;20(1):435-47 33 Citations |
| 1 | An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor. (Haverkos BM, McBride A, O'Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, Andritsos LA, Devine SM, Jaglowski SM) Bone Marrow Transplant 2014 Aug;49(8):1052-5 6 Citations |
| 1 | Genetics on a WHIM. (Al Ustwani O, Kurzrock R, Wetzler M) Br J Haematol 2014 Jan;164(1):15-23 42 Citations |
| 2 | Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. (Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M) J Clin Apher 2013 Oct;28(5):359-67 28 Citations |
| 1 | Salvage bone marrow harvest in patients failing plerixafor-based stem cell mobilization attempt: feasibility and autologous transplantation outcomes. (Kanate AS, Watkins K, Cumpston A, Craig M, Hamadani M) Biol Blood Marrow Transplant 2013 Jul;19(7):1133-5 4 Citations |
| 1 | Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. (Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, Deremer D, Jillella A, Craig M, Hamadani M) Bone Marrow Transplant 2013 Oct;48(10):1279-84 47 Citations |
| 1 | A locked, dimeric CXCL12 variant effectively inhibits pulmonary metastasis of CXCR4-expressing melanoma cells due to enhanced serum stability. (Takekoshi T, Ziarek JJ, Volkman BF, Hwang ST) Mol Cancer Ther 2012 Nov;11(11):2516-25 51 Citations |
| 1 | Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. (Duarte RF, Shaw BE, Marín P, Kottaridis P, Ortiz M, Morante C, Delgado J, Gayoso J, Goterriz R, Martínez-Chamorro C, Mateos-Mazón JJ, Ramírez C, de la Rubia J, Achtereekte H, Gandhi PJ, Douglas KW, Russell NH) Bone Marrow Transplant 2011 Jan;46(1):52-8 114 Citations |
| 1 | AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. (Larochelle A, Krouse A, Metzger M, Orlic D, Donahue RE, Fricker S, Bridger G, Dunbar CE, Hematti P) Blood 2006 May 01;107(9):3772-8 177 Citations |
| 1 | Synthesis of medium ring heterocycles using an intramolecular Heck reaction. (Arnold LA, Luo W, Guy RK) Org Lett 2004 Aug 19;6(17):3005-7 104 Citations |
| 1 | Tetravinyl-tetramethylcyclo-tetrasiloxane (tetravinyl D4) is a mutagen in Rat2lambda lacI fibroblasts. (Felix K, Lin S, Bornkamm GW, Janz S) Carcinogenesis 1998 Feb;19(2):315-20 5 Citations |
| 1 | Cerebral infarction: effects of dose and magnetization transfer saturation at gadolinium-enhanced MR imaging. (Mathews VP, King JC, Elster AD, Hamilton CA) Radiology 1994 Feb;190(2):547-52 67 Citations |
